Robert Canfield, Director of Marketing, Fresenius Kabi USA, LLC discusses the state of the infusion therapy sector.
Featured in 24×7 Magazine, 6-24-2022
In May, European IV pump provider Fresenius Kabi finalized its acquisition of infusion pump manufacturer Ivenix to expand its portfolio in the U.S. market. On the heels of this merger, Robert Canfield, director of marketing at Fresenius Kabi USA, LLC, sat down with 24×7 Magazine to discuss the state of the infusion therapy sector and whether concerns about infusion pump security are overblown.
24×7 Magazine: How has the COVID-19 pandemic impacted the infusion therapy sector?
Robert Canfield: The practice of moving the infusion pump outside the patient room continues to be a critically important consideration during these challenging times. We’ve seen many studies and opinions published about this practice; clinicians continue to share concerns about valid reasons against it. New technology is needed to adapt to these changing clinical conditions.
The Ivenix Infusion System addresses this challenge of adding extension sets and moving the pump just outside the door. The device can pump accurately in all clinical conditions and is the only infusion pump that measures and adjusts flow.
The Ivenix large-volume pump (LVP) can also automatically follow medication delivery with fluids to keep the patient sufficiently hydrated—and it can do this through a single line into a patient. This feature can also flush the medication that remains in the IV line, ensuring the patient receives the entire treatment as intended.
Moreover, visibility into a patient’s infusion status is even more critical in an isolation room setting. When an Ivenix infusion pump is placed inside a patient’s room, the large and bright display allows healthcare workers to safely see infusion status from meters away. The pump is also easy to clean and is tested to withstand repeated exposure to the harshest-rated disinfectants against coronavirus.
Nurses administering treatment and pharmacists can virtually follow and review a patient’s infusion status from a mobile device, see when bags are empty, and observe alarm conditions from anywhere in the hospital. The Ivenix Infusion System also provides a way to disseminate information without interrupting patient care. Rapidly evolving COVID-19 safety guidelines and drug regimens can be made available on Ivenix pumps in just minutes—and they’re just a “swipe away.”
24×7: What are some of the biggest innovations in the infusion therapy sector, and how are they influencing the design and development of infusion pumps?
Canfield: The mechanics of pumping technology has not changed dramatically for over a decade—until now. The most significant innovation we are now utilizing on patients is pneumatic pumping technology. Pneumatics allow the Ivenix LVP to measure and control an infusion to ensure a consistent delivery rate under all clinical conditions. This dosing accuracy is critical to providing quality event data that originates at the pump. When a traditional pump delivers at a different rate than the counter in the pump’s processor, the data reported to the electronic medical record (EMR) may be inaccurate. To achieve quality reporting, the system must start with quality fluid delivery.